Global Alzheimer’s Disease Market, By Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), Diagnostics (Magnetic Resonance Imaging, Lumbar Puncture Test, Electroencephalography, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Alzheimer’s Disease Market Analysis and Size
The Alzheimer’s disease market is anticipated to grow rapidly during the forecast period. In advanced stages of the disease, all memory and mental functions may be lost. According to the World Health Organization September 2021 report, around 55 million people worldwide suffer from dementia, with nearly 10 million cases recorded each year. According to the same source, Alzheimer's disease is the most common kind of dementia, accounting for 60-70 percent of all dementia cases. Because of the rising prevalence of Alzheimer's disease around the world, governments and non-governmental organizations are spending extensively in the development of diagnostics and therapies for the condition, which could boost market growth.
Data Bridge Market Research analyzes that the Alzheimer’s disease market which was USD 5.10 billion in 2022, is likely to reach USD 9.73 billion by 2030, and is expected to undergo a CAGR of 8.40% during the forecast period. “Magnetic resonance imaging” dominates the diagnostics segment of the Alzheimer’s disease market due to an increase in the demand of MRI for diagnosis of Alzheimer’s disease. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others), Diagnostics (Magnetic Resonance Imaging, Lumbar Puncture Test, Electroencephalography, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(U.S.), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Merz Pharma (Germany), AstraZeneca (U.K.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Biogen (U.S.), Siemens Healthcare GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
Alzheimer's disease is a neurological condition in which the brain shrinks (atrophy) and brain cells die. Alzheimer's disease is the most prevalent cause of dementia, which is characterised by a progressive loss of cognitive, behavioral, and social abilities that impairs a person's capacity to operate independently. Medications may improve or reduce the course of symptoms temporarily. These therapies can help patients with Alzheimer's disease keep function and independence for a short period of time. People with Alzheimer's disease and their caregivers can benefit from a variety of programmes and services.
Global Alzheimer’s Disease Market Dynamics
Drivers
- Growing prevalence and incidence
The global prevalence of Alzheimer's disease is steadily increasing due to the aging population and longer life expectancy. This rising prevalence drives the demand for diagnostic tools, treatments, and support services related to Alzheimer's disease.
- Drug development and innovation
There is a strong focus on research and development in the pharmaceutical industry to find effective treatments for Alzheimer's disease. Advances in drug discovery, clinical trials, and potential breakthrough therapies are significant drivers in this market, as they create opportunities for new products and treatment modalities.
- Increased awareness and early diagnosis
Greater public awareness and improved diagnostic methods have led to earlier detection of Alzheimer's disease. Early diagnosis is crucial in the management of the condition and can lead to more effective interventions and treatments.
- Growing investment for healthcare facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Personalized medicine and biomarker development
The identification and validation of biomarkers for Alzheimer's disease can provide opportunities for early diagnosis and personalized treatment strategies. Developing biomarker-based diagnostics and therapies can significantly impact the market by improving patient outcomes and management.
- Telemedicine and Remote Monitoring
The rise of telemedicine and remote monitoring technologies offers opportunities for providing Alzheimer's patients with better access to healthcare services and continuous monitoring. These technologies can enhance patient care, reduce caregiver burden, and create market opportunities for remote healthcare solutions.
Restraints
- Lack of effective treatment
One of the most significant restraints is the absence of a cure or highly effective disease-modifying treatment for Alzheimer's. Many clinical trials for potential therapies have failed, and the complexity of the disease makes drug development challenging, limiting treatment options.
- High development costs
Developing and bringing Alzheimer's drugs and therapies to market is an expensive and time-consuming process. High research and development costs, along with the risk of failure in clinical trials, can deter investment in the development of new treatments.
Challenges
- Lack of disease-modifying treatments
Despite ongoing research, there are currently no disease-modifying treatments available for Alzheimer's disease. Most available treatments focus on symptom management, leaving a critical unmet need for therapies that can alter the course of the disease.
- Disease complexity and heterogeneity
Alzheimer's disease is a complex and heterogeneous condition with various subtypes and stages. Understanding the disease's underlying mechanisms and developing effective treatments is challenging due to this complexity, making drug development and patient management difficult.
This Alzheimer’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Alzheimer’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Alzheimer’s Disease Market Scope
The Alzheimer’s disease market is segmented on the basis of type, therapeutics, diagnostics, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Early-Onset Alzheimer's
- Late-Onset Alzheimer's
- Familial Alzheimer's disease
Therapeutics
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Others
Diagnostics
- Magnetic Resonance Imaging
- Lumbar Puncture Test
- Electroencephalography
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Alzheimer’s Disease Market Regional Analysis/Insights
The Alzheimer’s disease market is analyzed and market size insights and trends are provided by country, type, therapeutics, diagnostics, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.
Asia-Pacific is expected to dominate the Alzheimer’s disease market because of the rising healthcare expenditure and growing prevalence of Alzheimer’s disease in this region. Additionally, rising number of population will further propel the market’s growth rate in this region.
North America is expected to show rapid growth during the forecast period due to rising number of research and development activities. U.S. is expected to dominate the region due to the growing focus of major key players on novel technology in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Alzheimer’s Disease Market Share Analysis
The Alzheimer’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Alzheimer’s disease market.
Some of the major players operating in the Alzheimer’s disease market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(U.S.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- Bristol-Myers Squibb Company (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Merz Pharma (Germany)
- AstraZeneca (U.K.)
- Amgen Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Biogen (U.S.)
- Siemens Healthcare GmbH (Germany)
SKU-